Live federal data · NADAC weekly · Part D CY24
Alprostadil Netarsudil and Latanoprost Ophthalmic Solution,
Alprostadil vs Netarsudil and Latanoprost Ophthalmic Solution, — $10693 of combined CY2024 Part D plan spend across 2 molecules. Side-by-side data, every number traced to its CMS or FDA source.
Last updated
NADAC: refreshed weeklyPart D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
Pick the drugs you want to compare.
Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.
Drug 1
Drug 2
Drug 3 (optional)
Drug 4 (optional)
Side by side, line by line.
Compare across
11 dimensions
Prostaglandin Analog
Netarsudil and Latanoprost Ophthalmic Solution,
Brand: Rocklatan
First FDA approval:
Lowest NADACAcquisition cost floor across all NDCs
$82.49Per unit
$139.51Per unit
Average NADACAcross all dosage forms and strengths
$151.55Up to $234.55
$139.51Up to $139.51
Generic manufacturersActive ANDA holders — FDA Orange Book
22 total ANDAs filed
00 total ANDAs filed
Annualized Part D spendCY2024 — CMS Part D Spending Dashboard
$10693Full year
—Full year
Part D claims (CY24)Total fills, all strengths
12— beneficiaries
—— beneficiaries
Avg cost per claimCalculated: total spend ÷ total claims
$891Per claim, all NDCs
—Per claim, all NDCs
Part D plans surveyed2026 plan year — CMS Formulary file
329Across CMS plan year
329Across CMS plan year
Prior-authorization frictionPlan-NDC pairs requiring PA
—Zero PA friction
2Minimal friction
Step therapy appliedPlan-NDC pairs requiring step therapy
—None
34Limited friction
FDA shortage statusLive cross-reference vs FDA Drug Shortage Database
NoneClear
NoneClear
Generic availableFDA Orange Book
Yes2 manufacturers
NoBrand-only